Rocket Pharmaceuticals (RCKT) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Rocket Pharmaceuticals (RCKT) Tops Q2 EPS by 10c

Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

August 9, 2021 4:01 PM EDT

Working with FDA on Changes to Clinical Trial Protocol in Danon Disease Trial; Rocket Anticipates Trial Will Resume in 3Q

Increasing and Durable Benefit Observed in Low Dose Cohort (6.7e13 dose) in Danon Disease; Removing Higher Dose Cohort (1.1e14 dose) From Future Dosing Plans; Full Clinical Update Expected in 4Q

Positive Results from FA, LAD-I, PKD Trials Presented at 24th ASGCT Annual Meeting Show Preliminary Evidence of Activity and Favorable Tolerability

Clinical Updates in FA, LAD-I, PKD and IMO Also Expected in 4Q

... More